APA

Fowler N. H., Davis R. E., Rawal S., Nastoupil L., Hagemeister F. B., McLaughlin P., Kwak L. W., Romaguera J. E., Fanale M. A., Fayad L. E., Westin J. R., Shah J., Orlowski R. Z., Wang M., Turturro F., Oki Y., Claret L. C., Feng L., Baladandayuthapani V., Muzzafar T., Tsai K. Y., Samaniego F. & Neelapu S. S. (20150223). Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. : The Lancet. Oncology.

Chicago

Fowler Nathan H, Davis R Eric, Rawal Seema, Nastoupil Loretta, Hagemeister Fredrick B, McLaughlin Peter, Kwak Larry W, Romaguera Jorge E, Fanale Michelle A, Fayad Luis E, Westin Jason R, Shah Jatin, Orlowski Robert Z, Wang Michael, Turturro Francesco, Oki Yasuhiro, Claret Linda C, Feng Lei, Baladandayuthapani Veerabhadran, Muzzafar Tariq, Tsai Kenneth Y, Samaniego Felipe and Neelapu Sattva S. 20150223. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. : The Lancet. Oncology.

Harvard

Fowler N. H., Davis R. E., Rawal S., Nastoupil L., Hagemeister F. B., McLaughlin P., Kwak L. W., Romaguera J. E., Fanale M. A., Fayad L. E., Westin J. R., Shah J., Orlowski R. Z., Wang M., Turturro F., Oki Y., Claret L. C., Feng L., Baladandayuthapani V., Muzzafar T., Tsai K. Y., Samaniego F. and Neelapu S. S. (20150223). Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. : The Lancet. Oncology.

MLA

Fowler Nathan H, Davis R Eric, Rawal Seema, Nastoupil Loretta, Hagemeister Fredrick B, McLaughlin Peter, Kwak Larry W, Romaguera Jorge E, Fanale Michelle A, Fayad Luis E, Westin Jason R, Shah Jatin, Orlowski Robert Z, Wang Michael, Turturro Francesco, Oki Yasuhiro, Claret Linda C, Feng Lei, Baladandayuthapani Veerabhadran, Muzzafar Tariq, Tsai Kenneth Y, Samaniego Felipe and Neelapu Sattva S. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. : The Lancet. Oncology. 20150223.